Legal
Following a court’s ruling last week over a partial clinical hold placed on the company in 2018 by the U.S. Food and Drug Administration, Vanda Pharmaceuticals said it is undertaking a “comprehensive review” of the decision and will then determine the next appropriate steps.
The active component of the drug, sodium valproate, has been on the market for epilepsy and bipolar disorder since 1967.
The U.S. Department of Justice has leveled more charges against members of the U.S. science community who have alleged ties to China.
In the complaint, the FTC alleged an “elaborate anticompetitive scheme to preserve a monopoly” on Daraprim.
Kapoor was found guilty in May 2019 of orchestrating kickback schemes to encourage doctors to boost prescriptions of Subsys, a powerful pain killer.
Collins, a former member of the Innate Immunotherapeutics Board of Directors, was indicted in 2018 and resigned his seat last year.
The first of the Insys Therapeutics executives found guilty of violating the Racketeer Influenced and Corrupt Organizations Act in May 2019 has been sentenced.
In a filing this week, the government said that tens of thousands of patients received “unreliable blood tests,” which deprived them of money and placed their health at risk.
As is often the case at the beginning and end of the year, a number of companies announced layoffs. Other news is related to lawsuits and an overall positive story about cancer death rates. Here’s a look.
A Chinese scientist living abroad who has been accused of accepting stolen intellectual property to benefit a pharma startup in China has been extradited to the United States.
PRESS RELEASES